Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery
Conditions
Interventions
JNJ-70033093 25 mg
JNJ-70033093 50 mg
+4 more
Locations
117
United States
Central Research Associates, Inc.
Birmingham, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
Bowen Hefley Orthopedics
Little Rock, Arkansas, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, United States
Denver Metro Orthopedics, PC
Englewood, Colorado, United States
DMI Research
Pinellas Park, Florida, United States
Start Date
June 17, 2019
Primary Completion Date
April 6, 2021
Completion Date
April 6, 2021
Last Updated
March 30, 2025
NCT07360392
NCT07058623
NCT04884542
NCT06080763
NCT05666479
NCT05592847
Lead Sponsor
Janssen Research & Development, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions